These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6255038)

  • 21. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62.
    Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of varicella-zoster virus-infected cell proteins that elicit antibody production during primary varicella using the immune transfer method.
    Palumbo PE; Arvin AM; Koropchak CM; Wittek AE
    J Gen Virol; 1984 Dec; 65 ( Pt 12)():2141-7. PubMed ID: 6096492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simian varicella virus antibody response in experimental infection of African green monkeys.
    Gray WL; Gusick NJ; Fletcher TM; Soike KF
    J Med Primatol; 1995 Dec; 24(4):246-51. PubMed ID: 8750501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ORF61 Protein Encoded by Simian Varicella Virus and Varicella-Zoster Virus Inhibits NF-κB Signaling by Interfering with IκBα Degradation.
    Whitmer T; Malouli D; Uebelhoer LS; DeFilippis VR; Früh K; Verweij MC
    J Virol; 2015 Sep; 89(17):8687-700. PubMed ID: 26085158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic value of varicella-zoster virus (VZV)-specific antibodies in the early phase of varicella in immunocompromized children.
    Nyerges G; Mészner Z; Simon M
    Acta Microbiol Hung; 1983; 30(3-4):211-5. PubMed ID: 6326459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody responses to early antigens of varicella-zoster virus (VZV) during varicella and zoster.
    Namazue J; Kato T; Yamanishi K; Takahashi M; Asano Y; Muraki R
    Biken J; 1986 Dec; 29(3-4):91-7. PubMed ID: 3039973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
    Murakami K; Matsuura M; Ota M; Gomi Y; Yamanishi K; Mori Y
    Vaccine; 2015 Nov; 33(45):6085-92. PubMed ID: 26116253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella.
    Koropchak CM; Graham G; Palmer J; Winsberg M; Ting SF; Wallace M; Prober CG; Arvin AM
    J Infect Dis; 1991 May; 163(5):1016-22. PubMed ID: 1850441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune evasion as a pathogenic mechanism of varicella zoster virus.
    Abendroth A; Arvin AM
    Semin Immunol; 2001 Feb; 13(1):27-39. PubMed ID: 11289797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simian varicella: a model for human varicella-zoster virus infections.
    Gray WL
    Rev Med Virol; 2004; 14(6):363-81. PubMed ID: 15386593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed-type hypersensitivity and in vitro lymphocyte response in guinea pigs immunized with a live varicella vaccine.
    Shiraki K; Yamanishi K; Takahashi M; Dohi Y
    Biken J; 1984 Mar; 27(1):19-22. PubMed ID: 6091616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and characterization of a live varicella vaccine (Oka strain).
    Takahashi M
    Biken J; 1984 Sep; 27(2-3):31-6. PubMed ID: 6100054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination.
    Jenke AC; Klein S; Baiker A; Wirth S; Sander M; Noelting C; Boecher O; Vizoso-Pinto MG
    Pediatr Infect Dis J; 2012 Nov; 31(11):1148-52. PubMed ID: 22863912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic understanding and control of varicella-zoster virus infection.
    Asano Y
    Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and molecular pathogenesis of varicella virus infection.
    Gilden DH; Cohrs RJ; Mahalingam R
    Viral Immunol; 2003; 16(3):243-58. PubMed ID: 14583142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody response to varicella-zoster virus after natural or vaccine-induced infection.
    Bogger-Goren S; Baba K; Hurley P; Yabuuchi H; Takahashi M; Ogra PL
    J Infect Dis; 1982 Aug; 146(2):260-5. PubMed ID: 6286790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varicella-zoster virus infection of diploid and chemically transformed guinea-pig embryo cells: factors influencing virus replication.
    Edmond BJ; Grose C; Brunell PA
    J Gen Virol; 1981 Jun; 54(Pt 2):403-7. PubMed ID: 6270257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varicella-zoster virus immunity in dermatological patients on systemic immunosuppressant treatment.
    Hackett CB; Wall D; Fitzgerald SF; Rogers S; Kirby B
    Br J Dermatol; 2011 Jun; 164(6):1387-9. PubMed ID: 21410679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular varicella-zoster virus infection in the guinea pig. A new in vivo model.
    Pavan-Langston D; Dunkel EC
    Arch Ophthalmol; 1989 Jul; 107(7):1068-72. PubMed ID: 2546523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.